The present disclosure relates to methods of determining complementarity scores and treatment based on the association between the blood-based T-cell receptor anti-viral CDR3s and viral antigens associated with worse overall survival for neuroblastoma subjects.

The present invention includes compositions and methods for detecting the presence of: a cytomegalovirus or an immune response relevant to a cytomegalovirus infection including T cells responsive to one or more cytomegalovirus peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences selected from those sequences set forth in Table 1 or Table 2, or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein comprising one or more amino acid sequences selected from those sequences set forth in Table 1 or Table 2; a pool of 2 or more peptides selected from the amino acid sequences set forth in Table 1 or Table 2; or a polynucleotide that encodes one or more peptides or proteins, comprising, consisting of, or consisting essentially of an amino acid sequence selected from those sequences set forth in Table 1 or Table 2, or a subsequence, portion, homologue, variant or derivative thereof. The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.